Table 1.
Characteristics of patients with AKI (n = 310).
Demographic Profiles and Comorbidities | |
Age (years), median (IQR) | 69 (58–79) |
Female, n (%) | 125 (40.32) |
BMI (kg/m2), median (IQR) | 24.73 (21.30–28.73) |
Baseline SCr (μmol/L), median (IQR) | 83.10 (60.11–127.30) |
Baseline eGFR (mL/min/1.73 m2), median (IQR) | 71.65 (41.76–105.43) |
Diabetes, n (%) | 135 (43.55) |
Hypertension, n (%) | 163 (52.58) |
Dyslipidemia, n (%) | 47 (15.16) |
CKD, n (%) | 129 (41.61) |
Heart Failure, n (%) | 54 (17.42) |
Vascular Disease, n (%) | 78 (25.16) |
Liver Disease, n (%) | 93 (30.00) |
Pulmonary Disease, n (%) | 36 (11.61) |
Malignancy, n (%) | 142 (45.81) |
Main Causes of AKI | |
Sepsis, n (%) | 188 (60.65) |
Cardiorenal Syndrome, n (%) | 22 (7.10) |
Hypovolemia, n (%) | 13 (4.19) |
Obstructive Uropathy, n (%) | 13 (4.19) |
Intrarenal Causes, n (%) | 74 (23.87) |
Hematologic and Biochemical Profiles at Diagnosis of AKI | |
SCr (µmol/L) at AKI Diagnosis, median (IQR) | 228.96 (151.16–375.70) |
eGFR (mL/min/1.73 m2) at AKI Diagnosis, median (IQR) | 22.53 (12.06–35.38) |
Hemoglobin (g/L), median (IQR) | 100.00 (88.00–117.00) |
Platelet (109/L), median (IQR) | 169.50 (101.25–253.75) |
BUN (mmol/L), median (IQR) | 19.99 (12.50–29.27) |
K (mmol/L), median (IQR) | 4.20 (3.60–4.90) |
Albumin (g/L), median (IQR) | 29.00 (25.00–33.90) |
Lactate (mmol/L), median (IQR) | 1.84 (1.29–3.46) |
pH, median (IQR) | 7.39 (7.30–7.45) |
HCO3 (mmol/L), median (IQR) | 21.05 (17.10–25.38) |
Bil-T (µmol/L), median (IQR) | 17.10 (10.26–51.31) |
RRT Status and 30-Day Mortality after AKI | |
RRT within 0–6 Days After AKI, n (%) | 40 (12.90) |
RRT within 7–14 Days After AKI, n (%) | 38 (12.26) |
30-Day Mortality After AKI, n (%) | 71 (22.90) |
AKI, acute kidney injury; BMI, body mass index; Bil-T, total bilirubin; BUN, blood urea nitrogen; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HCO3, blood bicarbonate; IQR, interquartile range; K, serum potassium; n, number; RRT, renal replacement therapy; SCr, serum creatinine.